Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03396926 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT03396926 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 44 participants.
The verdict
NCT03396926, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and best dose of capecitabine when given together with pembrolizumab and bevacizumab, and investigates how well they work in treating patients with microsatellite stable colorectal cancer that has spread to nearby tissues or lymph nodes, has spread to other places in the body, or that cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine together with pembrolizumab and bevacizumab may work better in treating patients with colorectal cancer.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Capecitabine
- BIOLOGICAL Bevacizumab
- PROCEDURE Specimen collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2024-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03396926
The ClinicalTrials.gov registry entry for NCT03396926 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03396926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03396926 about?
NCT03396926 is a clinical study titled "Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer". This phase II trial studies the side effects and best dose of capecitabine when given together with pembrolizumab and bevacizumab, and investigates how well they work in treating patients with microsatellite stable colorectal cancer that has spread to nearby tissues or lymph nodes, has spread to oth...
What is the current status of trial NCT03396926?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2018-04-18. Estimated completion is 2024-01-30.
What interventions are being tested in trial NCT03396926?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Capecitabine (DRUG), Bevacizumab (BIOLOGICAL), Specimen collection (PROCEDURE).
Who is sponsoring clinical trial NCT03396926?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.